US2023042095A1PendingUtilityA1
Antibodies against lif and uses thereof
Est. expiryDec 19, 2036(~10.4 yrs left)· nominal 20-yr term from priority
A61K 2039/505C07K 2317/92C07K 2317/567C07K 2317/565A61P 35/00C07K 16/244C07K 2317/41C07K 2317/24C07K 2317/34A61K 2039/55527C07K 16/248C07K 2317/33A61K 9/0085C07K 16/2896C07K 2317/76C07K 2317/21A61K 39/3955A61K 39/39558C07K 2299/00A61P 35/02A61K 39/395
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 .- 286 . (canceled)
287 . A recombinant antibody that specifically binds Leukemia Inhibitory Factor (LIF), the antibody comprising a heavy chain variable region with an amino acid sequence set forth in SEQ ID NO: 72, and a light chain variable region with an amino acid sequence set forth in SEQ ID NO: 76.
288 . The recombinant antibody of claim 287 , wherein the recombinant antibody binds to glycosylated LIF.
289 . The recombinant antibody of claim 287 , wherein the recombinant antibody is humanized.
290 . The recombinant antibody of claim 287 , wherein the recombinant antibody is deimmunized.
291 . The recombinant antibody of claim 287 , wherein the recombinant antibody comprises two heavy chains and two light chains.
292 . The recombinant antibody of claim 287 , wherein the recombinant antibody is an IgG antibody.Join the waitlist — get patent alerts
Track US2023042095A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.